Disease modification represents the future of CNS drug development. In this era, molecular markers of disease progression and drug activity will prove to be as necessary as the therapies themselves. At C2N Diagnostics, we are leading ways to provide new insights into the molecular mechanisms of brain diseases, track early progression, and measure the biologic activity of emerging therapies. By measuring the concentration and metabolism of CNS-derived biomolecules using sensitive stable isotope labeling, we provide novel insights into the normal and abnormal workings of the brain. Our ultimate goal? To accelerate the development of new therapies that will reverse or prevent neurodegeneration.

Biomarker Assays

CSF Markers

SILK-Aβ® (Total) SILK-Aβ® (Isoforms) SILK-Aβ® SPOT (Companion Dx Test) SILK-ApoE™ (Isoforms) SILK-sAPP™ (sAPPα and β) SISAQ-Aβ™ (Aβ Total and Isoforms) SISAQ™-Multi-Analyte Dementia Panel SILK-SOD1™

Plasma Markers

SILK-Aβ® (Total) SILK-Aβ® (Isoforms) SISAQ-Aβ™ (Aβ Total and Isoforms)

Bioanalytical Services

Preclinical

In vitro kinetic assays for drug screening Studies on a variety of animal models Lead candidate selection and/or validation

Phase I/IIa

Target engagement Dose optimization and scheduling Single and multiple dosing

Phase II

Mild cognitive impairment/AD PK/PD correlations Responders versus non-responders

Phase III/IV

Adaptive drug trials Drug responders Clinical endpoint validation (PD correlations)